Goodwill B (02256): Heyu Pharmaceuticals CSF-1R inhibitor Bejemer® was approved by the Chinese NMPA

Zhitong Finance App News, Heyu-B (02256) issued an announcement. On December 22, 2025, Shanghai Heyu Biomedical Technology Co., Ltd. (“NMPA”), a subsidiary of the company, announced that the China National Drug Administration (“NMPA”) has approved Bejiema® (pimitinib hydrochloride capsules) for adult patients with symptomatic tenosynovial giant cell tumors (“TGCT”) whose surgical removal may cause functional limitations or serious complications. After approval, Merck will promote the product to benefit TGCT patients in China as soon as possible.